Testosterone Enanthate Medicare Part D Coverage: What You'll Actually Pay in 2026

How Medicare Part D Classifies Testosterone Enanthate

Most Part D plans place generic testosterone enanthate on Tier 2 (preferred generic) or Tier 3 (non-preferred generic), which determines your copay at the pharmacy counter. The Centers for Medicare & Medicaid Services (CMS) requires all Part D sponsors to cover at least two drugs in each therapeutic class, and injectable androgens consistently appear on standard formularies because testosterone enanthate is the most widely prescribed testosterone formulation in the United States.

Tier placement varies by carrier. UnitedHealthcare's AARP plan, Humana's Enhanced plan, and CVS SilverScript each list testosterone enanthate injection (200 mg/mL) as a Tier 2 drug for 2026, which typically means a copay between $10 and $20 at preferred pharmacies. Plans that place it on Tier 3 may charge $30 to $45.

A critical detail: Part D covers FDA-approved manufactured products dispensed at retail or mail-order pharmacies. Compounded testosterone enanthate from a compounding pharmacy, even if prescribed by your doctor, is generally excluded from Part D coverage because compounded medications lack individual FDA approval. This matters because compounded testosterone enanthate averages roughly $80 per vial.

The 2026 Part D Benefit Structure and Your TRT Costs

The Inflation Reduction Act reshaped Part D cost-sharing starting in 2025, and the annual out-of-pocket cap of $2,000 remains in effect for 2026. This is the single most significant change for testosterone enanthate users on Medicare.

Here is how costs break down across coverage phases. During the deductible phase (up to $590 in 2026 for plans that apply one), you pay 100% of the negotiated price. A single vial of testosterone enanthate at the plan-negotiated rate typically runs $25 to $55, so TRT alone won't consume your entire deductible. During the initial coverage phase, you pay your tier-based copay ($10 to $45 per fill). Once your total out-of-pocket spending hits $2,000, you enter catastrophic coverage and pay $0 for the rest of the year.

For a beneficiary filling one 5 mL vial monthly at a $15 copay, the annual TRT cost through Part D is roughly $180. Even at the higher end ($45 copay), annual cost is $540. Neither scenario approaches the $2,000 cap on its own, but if you take other medications, the cap provides a hard ceiling on total prescription spending.

The old "donut hole" or coverage gap that previously forced patients to pay 25% coinsurance has been functionally replaced by the $2,000 cap. As CMS guidance for 2026 confirms, once you reach the cap, your plan and the federal government absorb all remaining costs.

Prior Authorization: What Your Doctor Needs to Submit

Most Part D plans require prior authorization (PA) before covering testosterone enanthate. The PA process confirms a diagnosis of male hypogonadism with supporting laboratory evidence. Plans typically require two morning serum total testosterone levels below 300 ng/dL, documented on separate days, consistent with the Endocrine Society's 2018 clinical practice guideline for testosterone therapy in men with hypogonadism.

Your prescriber submits the PA request along with lab results and clinical notes. Approval timelines vary. Standard review takes up to 72 hours. Expedited review, available when delay could seriously harm your health, requires a decision within 24 hours.

Common reasons for PA denial include: testosterone levels drawn in the afternoon (when values are naturally lower and less diagnostically reliable), a single lab draw instead of two confirmatory tests, or a diagnosis code that doesn't match hypogonadism (ICD-10 E29.1 for primary or E23.0 for secondary). If denied, your prescriber can file a coverage determination appeal. According to an analysis of Medicare Part D appeals data from CMS, approximately 50% to 60% of prior authorization denials are overturned at the first level of appeal when supporting documentation is resubmitted.

Dr. Bradley Anawalt, an endocrinologist at the University of Washington and co-author of the Endocrine Society guideline, has stated: "The threshold of 300 ng/dL is a reasonable but imperfect cutoff. Clinicians should consider symptoms alongside the lab value, and payers should allow clinical judgment to factor into coverage decisions."

Comparing Part D Coverage to Other Insurance Pathways

Part D is not the only way Medicare beneficiaries access testosterone enanthate. Part B covers drugs administered in a physician's office, and some men receive their injections at a clinic. In that scenario, testosterone enanthate is billed under Part B's "incident to" billing rules with a 20% coinsurance after the Part B deductible ($257 in 2026). The per-injection cost under Part B is often higher because it includes administration fees, but it may be preferable for patients who want supervised injections.

For beneficiaries comparing routes, the math depends on injection frequency and setting:

Self-injection at home (Part D): One 5 mL vial per month at $15 to $45 copay. Annual range: $180 to $540. No office visit costs.

Clinic injection (Part B): Biweekly office visits at 20% coinsurance on the drug plus administration. Annual range: $400 to $900 depending on clinic charges, but counts toward Part B's out-of-pocket limits.

Medicare Advantage (Part C): Many MA plans include Part D benefits (MA-PD). Formulary tiers and copays may differ from standalone Part D. Some MA-PD plans offer $0 copay tiers for preferred generics, which could reduce testosterone enanthate cost to nothing at the pharmacy.

Private insurance through an employer-sponsored plan or ACA marketplace plan typically covers testosterone enanthate with similar prior authorization requirements. Copays on commercial plans range from $5 to $50 depending on tier. The Testosterone Trials (TTrials), a set of seven coordinated placebo-controlled studies funded by NIH enrolling 790 men aged 65 and older with low testosterone, demonstrated benefits in sexual function, physical activity, and bone density, which strengthened the evidence base that insurers use to justify coverage of TRT in older men.

How to Get Testosterone Enanthate for Less on Medicare

Several practical strategies can reduce what you pay.

Use your plan's preferred pharmacy. Part D plans negotiate lower prices with specific pharmacy networks. Filling at a preferred pharmacy can cut your copay by 30% to 50% compared to a non-preferred pharmacy. Mail-order pharmacies (CVS Caremark, Express Scripts, Optum Rx) often offer the lowest copay tier and 90-day fills.

Request a 90-day supply. Many Part D plans allow a 90-day fill for maintenance medications, including testosterone enanthate. A 90-day fill typically costs 2 to 2.5 times the 30-day copay rather than 3 times, saving one copay's worth per quarter.

Apply for Extra Help (Low-Income Subsidy). Medicare's Extra Help program covers premium and cost-sharing assistance for beneficiaries with limited income and resources. In 2026, those who qualify pay no more than $4.50 for generic drugs per prescription. Given that testosterone enanthate is a generic, this reduces annual TRT cost to under $55.

Use manufacturer or pharmacy discount programs. While testosterone enanthate is a multi-source generic without a single manufacturer coupon, pharmacy discount programs such as GoodRx, RxSaver, and Cost Plus Drugs may offer cash prices below your Part D copay. Mark Cuban's Cost Plus Drugs lists testosterone cypionate (a pharmacologically near-identical ester) at roughly $10 for a 10 mL vial. This does not apply to the Part D out-of-pocket cap calculation, however, so paying cash means those dollars don't count toward your $2,000 threshold.

Compare plans during open enrollment. The Medicare Plan Finder tool at medicare.gov lets you enter your medications and pharmacy to compare total annual costs across Part D plans. A plan with a $15 testosterone enanthate copay and a $30 monthly premium will cost less overall than a plan with $0 copay but $65 premium.

Clinical Considerations That Affect Coverage Decisions

Part D plans don't just look at the diagnosis. They evaluate the clinical appropriateness of testosterone enanthate against alternatives. The FDA's prescribing information for testosterone enanthate specifies its indication as replacement therapy in males with conditions associated with deficiency or absence of endogenous testosterone, including primary hypogonadism and hypogonadotropic hypogonadism.

Some plans apply quantity limits. A standard quantity limit is 5 mL per 28 days, which aligns with the typical dosing of 100 to 200 mg every one to two weeks. If your prescribed dose requires more than 5 mL monthly, your prescriber may need to request a quantity limit exception with clinical justification.

The Pharmacological Interventions to Treat Male Hypogonadism study published in JAMA Network Open found that among 5.6 million commercially insured men diagnosed with hypogonadism between 2010 and 2019, injectable testosterone (enanthate and cypionate combined) accounted for 54.7% of all testosterone prescriptions. This high utilization supports formulary inclusion, but it also means plans scrutinize these claims more closely for appropriate diagnosis.

The Endocrine Society guideline recommends against testosterone therapy in men planning fertility in the near term, men with breast or prostate cancer, hematocrit above 50%, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, or uncontrolled heart failure. Plans may deny coverage if chart notes suggest any of these contraindications.

A second direct quotation from the guideline itself states: "We suggest measuring testosterone levels in the morning and repeating the measurement to confirm before making a diagnosis of testosterone deficiency." This two-test requirement is the most common documentation standard that Part D plans enforce.

Testosterone Enanthate vs. Cypionate on Medicare Formularies

Testosterone enanthate and testosterone cypionate are pharmacologically interchangeable esters with near-identical pharmacokinetic profiles. Most Part D plans cover both, but they may place one on a more favorable tier than the other based on negotiated rebates.

If your plan covers cypionate at Tier 2 but enanthate at Tier 3, switching ester saves money with no clinical difference. The half-life of enanthate is approximately 4.5 days; cypionate is approximately 5 days. Your prescriber can make this switch without dose adjustment.

Some plans do not distinguish between the two on their formulary and list both under the same tier. Check your plan's formulary or call the number on your Part D membership card to confirm. The 2022 American Urological Association guideline on testosterone deficiency treats both esters as clinically equivalent first-line options.

What Happens If You Lose Medicare Eligibility or Switch Plans

If you age into Medicare at 65 and are already on testosterone enanthate through a commercial plan, your Part D coverage begins on the first day of your initial enrollment period month. There is no gap in coverage if you enroll on time. Any prior authorization from your commercial plan does not transfer. Your new Part D plan will require its own PA.

If you switch Part D plans during Annual Enrollment (October 15 to December 7), the new plan starts January 1. Fill a 90-day supply in November or December to bridge the transition if the new plan requires a new PA.

Special Enrollment Periods (SEP) apply if you move, lose employer coverage, or qualify for Extra Help. During an SEP-triggered switch, request an expedited PA from the new plan. Most plans grant a one-time temporary supply (typically 30 days) while the PA is processed, per CMS transition policy rules.

Monitoring Requirements That May Affect Ongoing Coverage

Part D plans occasionally conduct drug utilization reviews (DUR) on long-term testosterone prescriptions. Your prescriber should document periodic monitoring consistent with guideline recommendations: hematocrit at baseline and at 3, 6, and 12 months, then annually, because testosterone can increase red blood cell production and raise the risk of polycythemia. The Endocrine Society guideline recommends checking hematocrit, PSA, and liver function tests at these intervals.

A hematocrit that rises above 54% may trigger a DUR flag, and the plan may request justification for continued therapy or a dose reduction. Similarly, plans may request updated testosterone levels to confirm the prescribed dose is maintaining levels within the target range of 450 to 600 ng/dL.

The TTrials bone density sub-study published in JAMA Internal Medicine demonstrated that one year of testosterone gel treatment increased volumetric bone mineral density of the spine by 7.5% compared to placebo in men over 65 with low testosterone (N=211). While this study used gel rather than injections, the finding reinforced the clinical rationale for long-term TRT coverage across formulations, including injectables covered under Part D.

Ongoing PA renewals are plan-specific. Some plans approve testosterone enanthate for 12 months; others grant indefinite approval after the initial PA. Ask your prescriber's office to confirm the approval duration and set a calendar reminder to re-submit documentation before expiration.